Skip to main content

CORRECTION article

Front. Cell. Infect. Microbiol., 23 June 2023
Sec. Molecular Viral Pathogenesis
Volume 13 - 2023 | https://doi.org/10.3389/fcimb.2023.1226054

Corrigendum: Drug repurposing approach against chikungunya virus: an in vitro and in silico study

This article is a correction to:

  1. Drug repurposing approach against chikungunya virus: an in vitro and in silico study

    1. Read original article
Bhagyashri Kasabe&#x;Bhagyashri Kasabe1†Gunwant Ahire&#x;Gunwant Ahire2†Poonam PatilPoonam Patil2Madhura PunekarMadhura Punekar2Kusuma Sai DavuluriKusuma Sai Davuluri2Mahadeo KakadeMahadeo Kakade2Kalichamy AlagarasuKalichamy Alagarasu2Deepti Parashar*Deepti Parashar2*Sarah Cherian*Sarah Cherian1*
  • 1Bioinformatics Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India
  • 2Dengue & Chikungunya Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India

A corrigendum on
Drug repurposing approach against chikungunya virus: an in vitro and in silico study

by Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) 13:1132538. doi: 10.3389/fcimb.2023.1132538

In the published article, there was an error in Table 4 as published. The target for metyrapone was listed twice while the target for lomibuvir was missed. The corrected Table 4 and its caption [Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose] appear below.

TABLE 4
www.frontiersin.org

Table 4 Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: chikungunya virus (CHIKV), drug repurposing, structural and non-structural proteins, in silico screening, in vitro validation

Citation: Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) Corrigendum: Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Front. Cell. Infect. Microbiol. 13:1226054. doi: 10.3389/fcimb.2023.1226054

Received: 20 May 2023; Accepted: 22 May 2023;
Published: 23 June 2023.

Edited and Reviewed by:

Daniel Salamango, Stony Brook University, United States

Copyright © 2023 Kasabe, Ahire, Patil, Punekar, Davuluri, Kakade, Alagarasu, Parashar and Cherian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Deepti Parashar, deeptiparasharster@gmail.com; Sarah Cherian, sarahcherian100@gmail.com

†These authors have equally contributed to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.